Dihydroartemisinin-piperaquine: if it works for control, can we use it for elimination?
Historically, antimalarial drugs have been used at a popu lation level in malaria-endemic areas with the objective of decreasing the burden, impact, and transmissibility of malaria.
1 Continuous chemo prophylaxis, once experimented but never seriously considered a feasible wide-scale implementable strategy, has been superseded by the concept of intermittent treatment targeting diff erent population groups, presenting many advantages, including non-interference with the acquisition of natural immunity against malaria. A fundamental premise for the use of any drug as part of population wide distribution eff orts, besides its effi cacy, is that the drug is suffi ciently safe so as to not to risk endangering the healthy individuals that will be exposed to it. The artemisinin-derived combination dihydroartemisinin-piperaquine (DP), registered under the European Medicines Agency in 2011, 2 would appear as an ideal candidate for the treatment of malaria, not only because of its high-demonstrated effi cacy, but on account of its excellent tolerability and good safety profi le, well reported in the literature. [3] [4] [5] From a preventive point of view, the long half-life of the partner drug piperaquine conveys protection of 22 days for adult patients and around 20 days for paediatric patients, 2 indicating a better post-treatment prophylactic eff ect than other combination therapies. 3, 6, 7 In the Lancet Infectious Diseases, Julie Gutman and colleagues analyse the safety, tolerability, and effi cacy of repeated doses of DP, for the treatment and prevention of malaria, with a particular focus on its use as intermittent preventive treatment (IPT). 8 Their meta-analysis, looking at over 4000 patients exposed to repeated courses of DP, substantiates the high effi cacy of this drug in terms of controlling malaria and all-cause hospital admission, and the good tolerability of repeated treatment schemes, with no evidence of arrhythmias secondary to the potential QT prolongation eff ect of cumulative doses of piperaquine after repeated doses. Although numbers are clearly insuffi cient to rule out this rare, life-threatening complication, and the small number of carefully ECG monitored patients calls for caution and further cardio safety studies, this analysis adds up to the growing body of evidence supporting the potential of this drug for IPT strategies. as an alternative to the currently recommended drugs. In areas where transmission remains high, it may be prudent to restrict ACTs for the treatment of cases, and not overexpose this drug family for prophylactic purposes. 9 The authors are, however, shy to extend their recommendations for the use of DP for elimination purposes. Indeed, many of the considerations that they ponder for the use of DP as IPT in restricted population groups, including repeated dosing, apply to its wider use in mass drug administration (MDA) campaigns that target the interruption of transmission. It is precisely DP's longer-lasting post-treatment prophylactic eff ect that is appealing as an elimination drug, being the basis for massive use in Zambia 10 and Mozambique 11 in ambitious malaria elimination demonstration projects. In elimination settings, careful pharmacovigilance should be coupled to the assessment of the eff ectiveness of drug deployment, and inform on the occurrence of rarer safety events, so as to help build a more defi nitive case for the adequacy of the chosen drug for MDA. If transmission is successfully interrupted, legitimate concerns on the risks of fuelling drug resistance should become less pressing.
Pregnant women and very young children are often neglected in the assessment of the effi cacy and safety of new drugs, or new uses of already existing drugs. For DP, this is not the case, and a robust portfolio of data has been compiled in recent years, both regarding the treatment and prevention of malaria during pregnancy 6, 12 and infancy 13 including the recent development of a dispersible paediatric formulation (NCT01992900). The safety and pharma cological interactions of IPTp-SP need to be assessed in HIV-positive pregnant women already receiving antiretrovirals, understanding that in this particularly vulnerable group, the use of sulphadoxinepyrimethamine is incompatible with cotrimoxazole prophylaxis.
Current WHO recommendations for the use of ACTS in pregnancy approach acceptance of ACT use throughout the entire pregnancy, because the risk-benefi t ratio still favours the quick elimination of malaria infections in vulnerable pregnant populations. 9 In MDA eff orts, however, use of ACTs in the fi rst term of pregnancy should not be recommended, as the risks of exposing healthy uninfected pregnant women outweigh the potential community benefi ts of interrupting transmission. For this reason, adequate pregnancy detection strategies are mandatory in malaria MDA eff orts using ACTs.
Debate is necessary for more proactive use of drugs to achieve the immensely ambitious goal of malaria eradication, but for the time being, DP seems to be a good candidate, both for IPT and elimination purposes. 
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